Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 20 peer-reviewed journal articles Updated
Genetics

Does NF1 Affect Life Expectancy? Facts & Outcomes

At a Glance

Many people with NF1 live full, normal lives. While the statistical average life expectancy is reduced by 8 to 15 years, this is heavily skewed by a subset of patients who develop severe complications like MPNSTs or cardiovascular issues. Proactive screening effectively manages these risks.

In this answer

2 sections

01

Understanding the Risks

02

How Proactive Care Improves Outcomes

Many people with Neurofibromatosis type 1 (NF1) live full, normal, and productive lives, and for many, the condition does not significantly impact how long they live [1]. However, studies do show that when looking at all people with NF1 as a group, the average life expectancy is reduced by about 8 to 15 years compared to the general population [2][3].

It is incredibly important to understand what this statistic actually means. This 8 to 15-year reduction is a statistical average—it is heavily skewed by a subset of patients who unfortunately experience rare but severe complications early in life [2]. The reduction in life expectancy is almost entirely linked to specific, manageable risks: certain types of cancer and cardiovascular issues [2][4]. With proactive monitoring and specialized care, you can manage these risks effectively and protect your long-term health [1][2].

Understanding the Risks

While most common NF1 symptoms—like café-au-lait spots and common skin bumps (cutaneous neurofibromas)—are completely benign and are not life-threatening, long-term health risks are usually linked to two main areas:

1. Cancer Risks (Malignancies)

Individuals with NF1 have a higher risk of developing certain cancers [2]. The most significant risks include:

  • Malignant Peripheral Nerve Sheath Tumors (MPNSTs): This is a type of soft tissue sarcoma and is the leading contributor to reduced life expectancy in NF1 [2]. Crucially, MPNSTs almost never develop from the common, small skin bumps (cutaneous neurofibromas) that many people with NF1 have. Instead, they can develop from deeper, often larger nerve tumors called plexiform neurofibromas, which are usually present from birth [5][4]. If you have a plexiform neurofibroma, rapid growth, hardening, or new, persistent pain in the tumor are “red flag” symptoms that require immediate medical attention [2][6].
  • Breast Cancer: Women with NF1 have a significantly higher risk of developing breast cancer, particularly before the age of 50 [7][8]. Regular screening usually needs to begin earlier—typically around age 30—and often includes both an annual mammogram and a breast MRI [9].
  • Brain and Central Nervous System Tumors: Certain tumors of the brain or spinal cord can affect long-term health [10]. Because doctors do not always order routine scans if you feel fine, it is very important to report new or severe symptoms like headaches, vision changes, weakness, or seizures.
  • Gastrointestinal Stromal Tumors (GISTs): These are rare tumors in the digestive tract that can occur in adults with NF1 and occasionally become malignant or cause internal bleeding [11].

2. Cardiovascular and Vascular Issues

NF1 can affect the blood vessels (a condition called vasculopathy), making them narrowed, thickened, or unusually fragile [12][13]. This can lead to:

  • High Blood Pressure (Hypertension): This is common in NF1 and can be caused by narrowed blood vessels leading to the kidneys (renal artery stenosis) or by a rare adrenal gland tumor called a pheochromocytoma [14][15]. If unchecked, a pheochromocytoma releases hormones that cause severe, sudden, and potentially life-threatening blood pressure spikes [16].
  • Arterial Complications: In rare cases, fragile blood vessels may bulge (aneurysms) or rupture, requiring emergency treatment [12][17].
  • Moyamoya Syndrome: A rare condition where blood vessels in the brain narrow, increasing stroke risk, particularly in children [18].

How Proactive Care Improves Outcomes

The most effective way to protect your long-term health is through lifelong, proactive surveillance [1][2]. General practitioners may not be familiar with the specific surveillance needs of NF1 patients, so seeking specialized care is essential.

  • Multidisciplinary Care: Adults and children should be evaluated regularly at a specialized NF1 clinic, which can coordinate your complex care needs across different medical specialties [2].
  • Early Detection: Catching MPNSTs early dramatically improves the chances of successful treatment [19]. Diagnostic tools like PET/CT scans help doctors determine if a benign tumor is changing into a cancer [20].
  • Routine Screening: Managing your risks means getting your blood pressure checked at least annually, starting breast cancer screenings at age 30 for women, and reporting any new or changing symptoms immediately [2][9].

Finally, sharing formal NF1 clinical care guidelines with your primary care provider is a great way to ensure your entire medical team is on the same page and fully prepared to support your long-term health [2].

Common questions in this guide

Does having NF1 mean I will have a shorter lifespan?
Not necessarily. Many people with NF1 live full, normal lives. While the statistical average life expectancy for the NF1 population is reduced by 8 to 15 years, this number is heavily skewed by a small group of patients who experience severe, rare complications.
What are the main causes of reduced life expectancy in NF1?
The primary risks that impact life expectancy in NF1 are certain types of cancer, particularly Malignant Peripheral Nerve Sheath Tumors (MPNSTs), and cardiovascular issues like high blood pressure and narrowed blood vessels.
Can the common skin bumps in NF1 turn into cancer?
No, the small skin bumps called cutaneous neurofibromas are benign and almost never turn into cancer. However, deeper tumors present from birth, called plexiform neurofibromas, can sometimes become malignant and require close monitoring.
What red flag symptoms should I watch for with plexiform neurofibromas?
You should seek immediate medical attention if you notice rapid growth, hardening, or new, persistent pain in a plexiform neurofibroma. These signs could indicate the tumor is changing or becoming cancerous.
Why do I need my blood pressure checked regularly if I have NF1?
NF1 can cause narrowed blood vessels or rare adrenal gland tumors (pheochromocytomas), both of which can lead to severe high blood pressure. Catching and treating high blood pressure early is critical for long-term cardiovascular health.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Do I (or my child) have any plexiform neurofibromas, and if so, how should we monitor them?
  2. 2.What are the specific "red flag" symptoms I should watch for that might indicate a plexiform neurofibroma is changing?
  3. 3.Should my blood pressure be monitored more frequently than at my annual check-up, and do I need testing for a pheochromocytoma or renal artery stenosis?
  4. 4.How do you coordinate with a specialized NF1 clinic to ensure we are following the most current surveillance guidelines?
  5. 5.What is the recommended timeline for my breast cancer screening, and should we include both mammograms and breast MRIs starting at age 30?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

Related questions

Can Genetic Testing Predict How Severe NF1 Will Be?Do Café-Au-Lait Spots Mean My Baby Has NF1?Do Cutaneous Neurofibromas Turn Into Cancer?Do Neurofibromas Grow Back After Surgical Removal?How to Find an NF1 Specialist for AdultsMild NF1 Symptoms: Can You Have Them Your Whole Life?What Are the Newest MEK Inhibitors for NF1?Does Neurofibromatosis (NF1) Cause High Blood Pressure?When Should Women With NF1 Start Breast Cancer Screening?Can Diet and Supplements Stop NF1 Tumor Growth?Does NF1 Cause Gastrointestinal Issues and GISTs?Will I Pass on NF1 If I'm the First in My Family?Does NF1 Cause Learning and Behavioral Issues?What Are the MPNST Warning Signs in NF1 Tumors?How to Screen for Optic Pathway Gliomas in NF1?What Are Selumetinib (Koselugo) Side Effects in NF1?How to Transition From Pediatric to Adult NF1 CareDo Asymptomatic NF1 Patients Need a Whole-Body MRI?Why is Radiation Avoided for NF1 Tumors?

References

References (20)
  1. 1

    Plexiform Neurofibroma: A Case Report.

    Bang K, Shenoi R, Waghchoure AV

    Cureus 2024; (16(7)):e65747 doi:10.7759/cureus.65747.

    PMID: 39211690
  2. 2

    Care of adults with neurofibromatosis type 1: a clinical practice resource of the American College of Medical Genetics and Genomics (ACMG).

    Stewart DR, Korf BR, Nathanson KL, et al.

    Genetics in medicine : official journal of the American College of Medical Genetics 2018; (20(7)):671-682 doi:10.1038/gim.2018.28.

    PMID: 30006586
  3. 3

    Pulmonary complications of type 1 neurofibromatosis.

    Reviron-Rabec L, Girerd B, Seferian A, et al.

    Revue des maladies respiratoires 2016; (33(6)):460-73.

    PMID: 26868668
  4. 4

    Neurofibromatosis from Head to Toe: What the Radiologist Needs to Know.

    Wang MX, Dillman JR, Guccione J, et al.

    Radiographics : a review publication of the Radiological Society of North America, Inc 2022; (42(4)):1123-1144 doi:10.1148/rg.210235.

    PMID: 35749292
  5. 5

    Genomics of MPNST (GeM) Consortium: Rationale and Study Design for Multi-Omic Characterization of NF1-Associated and Sporadic MPNSTs.

    Miller DT, Cortés-Ciriano I, Pillay N, et al.

    Genes 2020; (11(4)) doi:10.3390/genes11040387.

    PMID: 32252413
  6. 6

    Type I Neurofibromatosis: Case Report and Review of the Literature Focused on Oral and Cutaneous Lesions.

    Buchholzer S, Verdeja R, Lombardi T

    Dermatopathology (Basel, Switzerland) 2021; (8(1)):17-24 doi:10.3390/dermatopathology8010003.

    PMID: 33430291
  7. 7

    Breast cancer in neurofibromatosis type 1: overrepresentation of unfavourable prognostic factors.

    Uusitalo E, Kallionpää RA, Kurki S, et al.

    British journal of cancer 2017; (116(2)):211-217 doi:10.1038/bjc.2016.403.

    PMID: 27931045
  8. 8

    Breast cancer in neurofibromatosis 1: survival and risk of contralateral breast cancer in a five country cohort study.

    Evans DGR, Kallionpää RA, Clementi M, et al.

    Genetics in medicine : official journal of the American College of Medical Genetics 2020; (22(2)):398-406 doi:10.1038/s41436-019-0651-6.

    PMID: 31495828
  9. 9

    Breast cancer in a patient with neurofibromatosis type 1: A case report and review of literature.

    Canice Nwagbara VI, Ashindoitiang JA, Ugbem TI, et al.

    Rare tumors 2025; (17()):20363613251322866 doi:10.1177/20363613251322866.

    PMID: 39991119
  10. 10

    Distinctive Cancer Associations in Patients With Neurofibromatosis Type 1.

    Uusitalo E, Rantanen M, Kallionpää RA, et al.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2016; (34(17)):1978-86 doi:10.1200/JCO.2015.65.3576.

    PMID: 26926675
  11. 11

    Gastrointestinal stromal tumor in patient with neurofibromatosis type 1: A case report.

    Ibrahimi A, Lachkar S, Boualaoui I, et al.

    International journal of surgery case reports 2025; (129()):111166 doi:10.1016/j.ijscr.2025.111166.

    PMID: 40106943
  12. 12

    Spontaneous peripheral artery rupture in patients with neurofibromatosis type 1.

    Che L, Ge Y, Xu Y, et al.

    Journal of vascular surgery cases and innovative techniques 2025; (11(5)):101873 doi:10.1016/j.jvscit.2025.101873.

    PMID: 40697342
  13. 13

    [Rupture of Intercostal Aneurysm Associated with von Recklinghausen's Disease:Report of a Case].

    Sakamoto S, Kurumisawa S, Akutsu H, et al.

    Kyobu geka. The Japanese journal of thoracic surgery 2026; (79(2)):144-147.

    PMID: 42098017
  14. 14

    Hypertension in NF1: A closer look at the primacy of essential hypertension versus secondary causes.

    Loponen N, Ylä-Outinen H, Kallionpää RA, et al.

    Molecular genetics & genomic medicine 2024; (12(1)):e2346 doi:10.1002/mgg3.2346.

    PMID: 38131619
  15. 15

    Clinical Presentation and Outcomes of Phaeochromocytomas/Paragangliomas in Neurofibromatosis Type 1.

    Al-Sharefi A, Javaid U, Perros P, et al.

    European endocrinology 2019; (15(2)):95-100 doi:10.17925/EE.2019.15.2.95.

    PMID: 31616500
  16. 16

    An Autopsy Case of Sudden Death in Neurofibromatosis Type 1 With Pheochromocytoma and Myocarditis.

    Takamiya M, Niitsu H, Saigusa K

    The American journal of forensic medicine and pathology 2018; (39(1)):78-81 doi:10.1097/PAF.0000000000000367.

    PMID: 29210711
  17. 17

    Severe Hypertension Leading to Hemorrhagic Stroke in Neurofibromatosis Type 1.

    Faris M, Baliss M, Coni R, Nambudiri V

    Cureus 2021; (13(4)):e14658 doi:10.7759/cureus.14658.

    PMID: 33907652
  18. 18

    Characteristics of Moyamoya Syndrome in Pediatric Patients With Neurofibromatosis Type 1.

    Brosius SN, Vossough A, Fisher MJ, et al.

    Pediatric neurology 2022; (134()):85-92 doi:10.1016/j.pediatrneurol.2022.05.013.

    PMID: 35849956
  19. 19

    Malignant Transformation of Plexiform Neurofibroma Due to Neglected Giant Soft Tissue Swelling of the Back: A Case Report.

    Bin Abdul Halim WMA, Bin Mat Hassan S, Bt Awang M, Abdullah MAH

    Cureus 2024; (16(7)):e63807 doi:10.7759/cureus.63807.

    PMID: 39099914
  20. 20

    Foreign Body Abscess Mimicking a Malignant Peripheral Nerve Sheath Tumor in a Patient With Neurofibromatosis Type 1.

    Salamon J, Hagel C, Friedrich RE, et al.

    Clinical nuclear medicine 2015; (40(8)):674-5 doi:10.1097/RLU.0000000000000824.

    PMID: 26018702

This page is for informational purposes only and does not replace professional medical advice. Always consult your healthcare provider or a specialized NF1 clinic regarding your specific health risks and long-term prognosis.

Get notified when new evidence is published on Neurofibromatosis type 1.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.